Cell Therapeutics, Inc. (CTIC) Narrows Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Financial Fact:
Net loss attributable to CTI: -29.18M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Net loss attributable to CTI: -29.18M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Cell Therapeutics, Inc. (NASDAQ: CTIC) reported Q2 EPS of ($0.14), versus ($0.48) reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- World Acceptance (WRLD) Tops Q2 EPS by 113c
- Schlumberger Ltd. (SLB) Tops Q3 EPS by 2c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
